338 related articles for article (PubMed ID: 34245257)
21. Gene therapy in cystic fibrosis.
Armstrong DK; Cunningham S; Davies JC; Alton EW
Arch Dis Child; 2014 May; 99(5):465-8. PubMed ID: 24464978
[TBL] [Abstract][Full Text] [Related]
22. [Cystic fibrosis: molecular update and clinical implications].
Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
[TBL] [Abstract][Full Text] [Related]
23. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
Mickle JE; Cutting GR
Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
[TBL] [Abstract][Full Text] [Related]
24. New treatments targeting the basic defects in cystic fibrosis.
Fajac I; Wainwright CE
Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
[TBL] [Abstract][Full Text] [Related]
25. Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis-Learning from Other Diseases.
Mention K; Santos L; Harrison PT
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31117296
[TBL] [Abstract][Full Text] [Related]
26. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
[TBL] [Abstract][Full Text] [Related]
27. A new era of personalized medicine for cystic fibrosis - at last!
Quon BS; Wilcox PG
Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
[TBL] [Abstract][Full Text] [Related]
28. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
29. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
[TBL] [Abstract][Full Text] [Related]
30. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
Fanen P; Wohlhuter-Haddad A; Hinzpeter A
Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?
Purushothaman AK; Natarajan S; Panigrahi T; Nelson EJR
J Biosci; 2024; 49():. PubMed ID: 38920104
[TBL] [Abstract][Full Text] [Related]
32. [Evidence-based treatment of cystic fibrosis].
Ringshausen FC; Hellmuth T; Dittrich AM
Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
[TBL] [Abstract][Full Text] [Related]
33. Advances in the diagnosis and treatment of cystic fibrosis.
Martiniano SL; Hoppe JE; Sagel SD; Zemanick ET
Adv Pediatr; 2014 Aug; 61(1):225-43. PubMed ID: 25037130
[TBL] [Abstract][Full Text] [Related]
34. Treating Cystic Fibrosis with mRNA and CRISPR.
Da Silva Sanchez A; Paunovska K; Cristian A; Dahlman JE
Hum Gene Ther; 2020 Sep; 31(17-18):940-955. PubMed ID: 32799680
[TBL] [Abstract][Full Text] [Related]
35. Molecular Diagnosis of Cystic Fibrosis.
Deignan JL; Grody WW
Curr Protoc Hum Genet; 2016 Jan; 88():9.28.1-9.28.6. PubMed ID: 26724724
[TBL] [Abstract][Full Text] [Related]
36. Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator.
Mekus F; Ballmann M; Bronsveld I; Dörk T; Bijman J; Tümmler B; Veeze HJ
Hum Genet; 1998 May; 102(5):582-6. PubMed ID: 9654209
[TBL] [Abstract][Full Text] [Related]
37. [Cystic fibrosis: From gene discovery to precision medicine].
Férec C
Med Sci (Paris); 2021; 37(6-7):618-624. PubMed ID: 34180821
[TBL] [Abstract][Full Text] [Related]
38. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF.
Egan ME
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Root Cause of Cystic Fibrosis.
Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
[TBL] [Abstract][Full Text] [Related]
40. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
